Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231 patients (116 countries), 3127 patients (2.2%) had a pre-operative SARS-CoV-2 diagnosis. Adjusted 30-day mortality in patients without SARS-CoV-2 infection was 1.5% (95%CI 1.4-1.5). In patients with a pre-operative SARS-CoV-2 diagnosis, mortality was increased in patients having surgery within 0-2 weeks, 3-4 weeks and 5-6 weeks of the diagnosis (odds ratio (95%CI) 4.1 (3.3-4.8), 3.9 (2.6-5.1) and 3.6 (2.0-5.2), respectively). Surgery performed ≥ 7 weeks after SARS-CoV-2 diagnosis was associated with a similar mortality risk to baseline (odds ratio (95%CI) 1.5 (0.9-2.1)). After a ≥ 7 week delay in undertaking surgery following SARS-CoV-2 infection, patients with ongoing symptoms had a higher mortality than patients whose symptoms had resolved or who had been asymptomatic (6.0% (95%CI 3.2-8.7) vs. 2.4% (95%CI 1.4-3.4) vs. 1.3% (95%CI 0.6-2.0), respectively). Where possible, surgery should be delayed for at least 7 weeks following SARS-CoV-2 infection. Patients with ongoing symptoms ≥ 7 weeks from diagnosis may benefit from further delay.
Severe acute respiratory syndrome coronavirus 2 pandemic capacity is derived from the unique structural features on its spike protein: fast viral surfing over the epithelium with flat N‐terminal domain, tight binding to ACE2 entry receptor, and furin protease utilization. In addition, the possible involvement of other components such as lipid rafts, CLRs, and neuropilin is, in combination, mediating the accelerated cell entry and other critical steps in its overwhelming contagious capacity and pandemy.
At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand.
Graphical abstract:
Therapeutic options for the highly pathogenic human severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) causing the current pandemic coronavirus disease (COVID-19)
are urgently needed. COVID-19 is associated with viral pneumonia and acute respiratory
distress syndrome causing significant morbidity and mortality. The proposed treatments
for COVID-19 have shown little or no effect in the clinic so far. Additionally,
bacterial and fungal pathogens contribute to the SARS-CoV-2-mediated pneumonia disease
complex. The antibiotic resistance in pneumonia treatment is increasing at an alarming
rate. Therefore, carbon-based nanomaterials (CBNs), such as fullerene, carbon dots,
graphene, and their derivatives constitute a promising alternative due to their
wide-spectrum antimicrobial activity, biocompatibility, biodegradability, and capacity
to induce tissue regeneration. Furthermore, the antimicrobial mode of action is mainly
physical (
e.g.
, membrane distortion), characterized by a low risk of
antimicrobial resistance. In this Review, we evaluated the literature on the antiviral
activity and broad-spectrum antimicrobial properties of CBNs. CBNs had antiviral
activity against 13 enveloped positive-sense single-stranded RNA viruses, including
SARS-CoV-2. CBNs with low or no toxicity to humans are promising therapeutics against
the COVID-19 pneumonia complex with other viruses, bacteria, and fungi, including those
that are multidrug-resistant.
In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.
tropism/adaptation, resistance to neutralizing antibodies, or immune evasion. 2 Interestingly, clinical SARS-CoV-2 isolates to date have only a single high-frequency nonsynonymous mutation, D614G, in their S protein. 9 Based on currently known mutation rates and patterns in clinical isolates of SARS-CoV-2, the S protein does not appear to be a mutational "hot spot" for SARS-CoV-2, unlike other human CoVs. SARS-CoV-2 is the seventh HCoV, but the first HCoV with pandemic potential. SARS-CoV disappeared without a pandemic, and MERS-CoV is mostly endemic to the Arabian Peninsula with some additional limited traveler infections resulting in outbreaks in South Korea. 3,4 These unique features of SARS-CoV-2 raise several questions concerning the proximal origin of the virus that require further discussion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.